Icotinib for Completed Resected IB NSCLC With EGFR Mutation

Exclusion Criteria

• •Had had previous chemotherapy, radiotherapy, or agents directed at the HER axis (e.g. erlotinib, gefitinib, cetuximab, trastuzumab).
• •Inability to comply with protocol or study procedures.
• •Had a history another malignancy in the last 5 years with the exception of cured basal cell carcinoma of the skin, cured in situ carcinoma of the uterine cervix and cured epithelial carcinoma of the bladder.
• •Any evidence confirmed tumor recurrence before investigational therapy.
• •Known severe hypersensitivity to icotinib or any of the excipients of this product.
• •Evidence of clinically active interstitial lung disease.
• •Eye inflammation not fully controlled or conditions predisposing the subject to this.
• •Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease).
• •Known human immunodeficiency virus (HIV) infection.
• •Pregnancy or breast-feeding women.
• •Ingredients mixed with small cell lung cancer patients.
• •History of neurologic or psychiatric disorders.